177 related articles for article (PubMed ID: 19663769)
1. Clinical development of inhibitors of the insulin-like growth factor receptor in oncology.
Gualberto A; Pollak M
Curr Drug Targets; 2009 Oct; 10(10):923-36. PubMed ID: 19663769
[TBL] [Abstract][Full Text] [Related]
2. Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions.
Gualberto A; Pollak M
Oncogene; 2009 Aug; 28(34):3009-21. PubMed ID: 19581933
[TBL] [Abstract][Full Text] [Related]
3. Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review.
Ozkan EE
Mol Cell Endocrinol; 2011 Sep; 344(1-2):1-24. PubMed ID: 21782884
[TBL] [Abstract][Full Text] [Related]
4. Blocking the insulin-like growth factor-I receptor as a strategy for targeting cancer.
Hofmann F; García-Echeverría C
Drug Discov Today; 2005 Aug; 10(15):1041-7. PubMed ID: 16055020
[TBL] [Abstract][Full Text] [Related]
5. Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials.
Rodon J; DeSantos V; Ferry RJ; Kurzrock R
Mol Cancer Ther; 2008 Sep; 7(9):2575-88. PubMed ID: 18790742
[TBL] [Abstract][Full Text] [Related]
6. Insulin-like growth factor receptor signaling in tumorigenesis and drug resistance: a challenge for cancer therapy.
Hua H; Kong Q; Yin J; Zhang J; Jiang Y
J Hematol Oncol; 2020 Jun; 13(1):64. PubMed ID: 32493414
[TBL] [Abstract][Full Text] [Related]
7. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma.
Wang Z; Chakravarty G; Kim S; Yazici YD; Younes MN; Jasser SA; Santillan AA; Bucana CD; El-Naggar AK; Myers JN
Clin Cancer Res; 2006 Aug; 12(15):4755-65. PubMed ID: 16899627
[TBL] [Abstract][Full Text] [Related]
8. Targeting the insulin-like growth factor signaling pathway: figitumumab and other novel anticancer strategies.
Yap TA; Olmos D; Molife LR; de Bono JS
Expert Opin Investig Drugs; 2011 Sep; 20(9):1293-304. PubMed ID: 21777167
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal antibodies against components of the IGF system for cancer treatment.
Feng Y; Dimitrov DS
Curr Opin Drug Discov Devel; 2008 Mar; 11(2):178-85. PubMed ID: 18283605
[TBL] [Abstract][Full Text] [Related]
10. The insulin-like growth factor (IGF) axis as an anticancer target in prostate cancer.
Heidegger I; Massoner P; Sampson N; Klocker H
Cancer Lett; 2015 Oct; 367(2):113-21. PubMed ID: 26231734
[TBL] [Abstract][Full Text] [Related]
11. Resistance pathways relevant to insulin-like growth factor-1 receptor-targeted therapy.
Hendrickson AW; Haluska P
Curr Opin Investig Drugs; 2009 Oct; 10(10):1032-40. PubMed ID: 19777391
[TBL] [Abstract][Full Text] [Related]
12. Customizing the targeting of IGF-1 receptor.
Baserga R
Future Oncol; 2009 Feb; 5(1):43-50. PubMed ID: 19243297
[TBL] [Abstract][Full Text] [Related]
13. Molecular predictors of response to a humanized anti-insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer.
Zha J; O'Brien C; Savage H; Huw LY; Zhong F; Berry L; Lewis Phillips GD; Luis E; Cavet G; Hu X; Amler LC; Lackner MR
Mol Cancer Ther; 2009 Aug; 8(8):2110-21. PubMed ID: 19671761
[TBL] [Abstract][Full Text] [Related]
14. IGF-1 receptor inhibitors in clinical trials--early lessons.
Weroha SJ; Haluska P
J Mammary Gland Biol Neoplasia; 2008 Dec; 13(4):471-83. PubMed ID: 19023648
[TBL] [Abstract][Full Text] [Related]
15. A phase 2 study of the insulin-like growth factor-1 receptor inhibitor MK-0646 in patients with metastatic, well-differentiated neuroendocrine tumors.
Reidy-Lagunes DL; Vakiani E; Segal MF; Hollywood EM; Tang LH; Solit DB; Pietanza MC; Capanu M; Saltz LB
Cancer; 2012 Oct; 118(19):4795-800. PubMed ID: 22437754
[TBL] [Abstract][Full Text] [Related]
16. Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors in cancer therapy: advances and perspectives.
Xue M; Cao X; Zhong Y; Kuang D; Liu X; Zhao Z; Li H
Curr Pharm Des; 2012; 18(20):2901-13. PubMed ID: 22571659
[TBL] [Abstract][Full Text] [Related]
17. Targeting insulin-like growth factor in breast cancer therapeutics.
Karamouzis MV; Papavassiliou AG
Crit Rev Oncol Hematol; 2012 Oct; 84(1):8-17. PubMed ID: 22424863
[TBL] [Abstract][Full Text] [Related]
18. The potential role of insulin-like growth factor receptor inhibitors in the treatment of advanced non-small cell lung cancer.
Gridelli C; Rossi A; Bareschino MA; Schettino C; Sacco PC; Maione P
Expert Opin Investig Drugs; 2010 May; 19(5):631-9. PubMed ID: 20367288
[TBL] [Abstract][Full Text] [Related]
19. Advances in targeting insulin-like growth factor signaling pathway in cancer treatment.
You L; Liu C; Tang H; Liao Y; Fu S
Curr Pharm Des; 2014; 20(17):2899-911. PubMed ID: 23944362
[TBL] [Abstract][Full Text] [Related]
20. Targeting the insulin-like growth factor axis for the development of novel therapeutics in oncology.
Gao J; Chang YS; Jallal B; Viner J
Cancer Res; 2012 Jan; 72(1):3-12. PubMed ID: 22215692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
